Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P14416

UPID:
DRD2_HUMAN

ALTERNATIVE NAMES:
Dopamine D2 receptor

ALTERNATIVE UPACC:
P14416; Q9NZR3; Q9UPA9

BACKGROUND:
The Dopamine D2 receptor, identified by the UniProt accession P14416, is a key player in neurotransmitter regulation, inhibiting adenylyl cyclase via G protein signaling. It has a significant role in the regression of hyaloid vessels in the retina, mediated by the suppression of VEGFR2/KDR, potentially influenced by OPN5.

THERAPEUTIC SIGNIFICANCE:
Exploring the D(2) dopamine receptor's functions offers promising avenues for therapeutic intervention. Its regulatory role in dopamine signaling and vascular biology presents it as a target for drug discovery in neurological and retinal disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.